Key result
VTE prophylaxis with enoxaparin once daily showed no significant difference in major bleeding events compared to once daily in underweight critically ill patients.
Why the study?
Does enoxaparin 30 mg once daily reduce clinically significant bleeding compared to 40 mg once daily in critically ill underweight patients?
Cohort (n=310)
Yes
Does enoxaparin 30 mg once daily reduce clinically significant bleeding compared to 40 mg once daily in critically ill underweight patients?
In critically ill underweight patients, enoxaparin 30 mg daily and 40 mg daily for VTE prophylaxis showed no significant difference in major bleeding or VTE incidence.
Answers are grounded in this paper and cite their sources.
No difference in major bleeding across enoxaparin doses in underweight patients; leaves open optimal VTE prophylaxis strategy.
Purpose: Optimal dosing of VTE prophylaxis for specific patient populations remains an area of concern as insufficient evidence exists regarding dosing for underweight patients. The purpose of this study is to compare the incidence of major bleeding events in underweight patients given different prophylactic doses of enoxaparin. Methods: This is a retrospective analysis performed at multiple hospitals within a single health care system. Patients with a BMI < 18.5 kg/m 2 were divided into 2 groups depending on whether they received at least 1 prophylactic dose of enoxaparin 30 mg subcutaneously once daily or enoxaparin 40 mg subcutaneously once daily. Underweight adult patients were included if they were admitted to an ICU for at least 48 hours and received at least 1 dose of enoxaparin for VTE prophylaxis during their ICU admission. The primary aim was to compare the incidence of clinically significant bleeding between dosing strategies. Secondary aims included the incidence of VTE during admission, ICU length of stay, overall hospital length of stay, and all-cause mortality 30 days post-discharge. Results: A total of 310 patients met inclusion criteria for this study, with 80 patients in the 30 mg group and 230 patients in the 40 mg group. There was no significant difference in major bleeding events between the 2 groups ( P = .61). No significant differences in incidence of VTE ( P = .455 ), ICU length of stay ( P = .466), overall hospital stay ( P = .502), or all-cause mortality ( P = .925) were found between groups. Conclusions: No difference was found in clinically significant bleeding between underweight critically ill patients receiving VTE prophylaxis with enoxaparin 30 mg once daily or 40 mg once daily. Further studies are needed to evaluate the optimal dosing of VTE prophylaxis with enoxaparin in underweight patients.
No takes yet. Share an insight, caveat, or question.
Meester et al. (2025) conducted a cohort in Critically ill underweight patients requiring VTE prophylaxis (n=310). Enoxaparin vs. Enoxaparin 40 mg subcutaneously once daily was evaluated on Incidence of clinically significant bleeding (p=.61). VTE prophylaxis with enoxaparin once daily showed no significant difference in major bleeding events compared to once daily in underweight critically ill patients.
Synapse has enriched 10 related papers. Consider them for comparative context: